A Phase 1/2 interventional study of Budesonide and Budesonide in Rhinosinusitis and Chronic Polyposis, sponsored by Pari Pharma GmbH. Completed at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-12.
Sponsored by Pari Pharma GmbH · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Rhinosinusitis with a site in Germany — 3 open to participants now, 7 under way, 4 of them phase 3. Rhinosinusitis · Germany.
Among the 21 studies in Rhinosinusitis with a site in Germany, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2013, is one of 2 in phase 1/2, and was the 6th registered.
252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.
Browse Rhinosinusitis studies →3 of the 21 studies in Rhinosinusitis with a site in Germany are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Germany
Ages 18–130
The European Forum for Research and Education in Allergy and Airway Diseases · Sites in Germany, United States, Belgium and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Germany, United States, Argentina and 17 more countries
Ages 12+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 74 across 177 interventional studies indexed under Rhinosinusitis.
Median enrollment 216 across the 15 interventional studies, 184 across the 6 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 10 most frequent:
Pari Pharma GmbH is the lead sponsor of 5 studies on the registry; none are open to participants now.
Pari Pharma GmbH has 2 studies filed under Rhinosinusitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Rhinosinusitis with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706817Phase 3AstraZenecaA Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | 2027-01-13 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT04959448Regeneron PharmaceuticalsStudy Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) | 2027-03-25 |
| NCT06970977The European Forum for Research and Education in Allergy and Airway DiseasesCRS Questionnaire Validation Project | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Rhinosinusitis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the selected parameter should allow a correlation between an objective methodology and the clinical outcome of the study patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Buparid 1 mg budesonide/2 ml nebuliser solution
Drug: Budesonide
Budes® Nasal Spray 50 µg budesonide/pump
Drug: Budesonide
Inhalation
Nasal spray
Change of Inflammation of the Nasal Mucosa and Paranasal Sinus
Inflammation of the nasal mucosa and paranasal sinus was assessed using the Lund-Mackay score based on magnetic resonance imaging. The score can take on values between 0 and 24 points, with higher values indicating more severe impairment. The outcome investigated is the intraindividual mean score of 2 independent raters assessing the same images.
Time frame: Change from Baseline to Week 8
Safety Assessment
Treatment-emergent adverse events (AEs) Each participant has been monitored for adverse events up to 26 weeks. All patients withdrawn from the study will be followed-up for AEs or SAEs for further 2 weeks or 4 weeks, respectively.
Time frame: up to 26 weeks
Health-specific Quality of Life
Health-specific quality of life was assessed by means of the self-rated, 22-item Sino-Nasal Outcome Test (SNOT-22). The SNOT-22 total score has a (theoretical) range of 0 - 110 points, with higher scores indicating more severe impairment. Presented are the mean values of the SNOT-22 total score after 24 weeks minus value at day 0 (baseline).
Time frame: 24 weeks
Nasal Obstruction
Nasal obstruction was assessed using the method of rhinomanometry by measuring the positive nasal inspiratory flow (PNIF). For the assessment the subject had to inhale maximally through the nose three times and the highest value of flow rate was recorded after 4 weeks and 8 weeks of treatment.
Time frame: 4 weeks / 8 weeks
4 patients not randomised
| Milestone | Buparid; Treatment A | Budes; Treatment B |
|---|---|---|
| Started | 8 | 6 |
| Completed | 8 | 6 |
| Not completed | 0 | 0 |
Inflammation of the nasal mucosa and paranasal sinus was assessed using the Lund-Mackay score based on magnetic resonance imaging. The score can take on values between 0 and 24 points, with higher values indicating more severe impairment. The outcome investigated is the intraindividual mean score of 2 independent raters assessing the same images.
| units on a scale | Buparid; Treatment A | Budes; Treatment B |
|---|---|---|
| Change of Inflammation of the Nasal Mucosa and Paranasal Sinus | -2 (-3.5 to 2.5) | -0.8 (-3.5 to 1) |
Treatment-emergent adverse events (AEs) Each participant has been monitored for adverse events up to 26 weeks. All patients withdrawn from the study will be followed-up for AEs or SAEs for further 2 weeks or 4 weeks, respectively.
| Participants | Buparid; Treatment A | Budes; Treatment B |
|---|---|---|
| Safety Assessment | 5 | 4 |
Health-specific quality of life was assessed by means of the self-rated, 22-item Sino-Nasal Outcome Test (SNOT-22). The SNOT-22 total score has a (theoretical) range of 0 - 110 points, with higher scores indicating more severe impairment. Presented are the mean values of the SNOT-22 total score after 24 weeks minus value at day 0 (baseline).
| score on a scale | Buparid; Treatment A | Budes; Treatment B |
|---|---|---|
| Health-specific Quality of Life | 23.6 (19.7 to 27.6) | 14.4 (9.8 to 18.9) |
Nasal obstruction was assessed using the method of rhinomanometry by measuring the positive nasal inspiratory flow (PNIF). For the assessment the subject had to inhale maximally through the nose three times and the highest value of flow rate was recorded after 4 weeks and 8 weeks of treatment.
| ml/sec | Buparid; Treatment A | Budes; Treatment B |
|---|---|---|
| Mean flow rate after 4 weeks | 746 (462 to 1031) | 574 (267 to 881) |
| Mean flow rate after 8 weeks | 755 (644 to 867) | 646 (527 to 765) |
Collected over Each participant has been monitored for adverse events up to 48 weeks. All patients withdrawn from the study will be followed-up for AEs or SAEs for further 2 weeks or 4 weeks, respectively.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Buparid; Treatment A | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Budes; Treatment B | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Buparid; Treatment A | Budes; Treatment B |
|---|---|---|
| Nasal DrynessRespiratory, thoracic and mediastinal disorders | 1/8 | 1/6 |
| Sputum IncreasedRespiratory, thoracic and mediastinal disorders | 0/8 | 1/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/8 | 1/6 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 0/8 | 1/6 |
| DepressionPsychiatric disorders | 0/8 | 1/6 |
| Sensitive SkinSkin and subcutaneous tissue disorders | 0/8 | 1/6 |
| Otitis mediaInfections and infestations | 0/8 | 1/6 |
| NasopharyngitisInfections and infestations | 1/8 | 1/6 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/8 | 0/6 |
| ParosmiaNervous system disorders | 1/8 | 0/6 |
| Age, Categorical(Participants) | Buparid; Treatment A | Budes; Treatment B | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 6 | 14 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Buparid; Treatment A | Budes; Treatment B | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 5 | 3 | 8 |
| Race and Ethnicity Not Collected(Participants) | Buparid; Treatment A | Budes; Treatment B | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Buparid; Treatment A | Budes; Treatment B | Total |
|---|---|---|---|
| Germany | 8 | 6 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2013 to primary completion in Feb 2020, 77 months.
Results were first posted in Apr 2022, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide
Pari Pharma GmbH